Videos: Gene and Cell Therapy

This production outlines the lymphoma research currently being undertaken in Oxford. We hear from both patient and clinician participants in clinical trials. The production covers: 1. The importance of taking part in research for both patients and clinicians 2. The scope of research 3. Collaboration and teamwork in research 4. The advantages of being part of a clinical trial If you would like further information please check out the following links: Oxford BRC Haematology: https://oxfordbrc.nihr.ac.uk/research-themes-overview/haematology-and-stem-cells/ NIHR https://www.nihr.ac.uk Oxford lymphoid disorders study group https://www.cancercentre.ox.ac.uk/research/consortia/oxford-lymphoid-disorders-study-group/ EPCTU https://www.oncology.ox.ac.uk/research/srf/early-phase-clinical-trials-unit Oxford Centre for Haematology https://www.rdm.ox.ac.uk/about/our-clinical-facilities-and-mrc-units/och

In this video, Graham Collins, MBBS, MRCP, FRCPath, DPhil, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, explains how the NHS in the UK have handled the roll-out of CAR T-cell therapy to date. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Dr Collins mentions the importance of pooling together the experience from centers in order to ensure correct protocols are in place for adverse events, and that patients are directed to the right centers in a timely manner.This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).

Adam Mead, MRCP, FRCPath from Oxford University Hospitals, Oxford, UK discusses his presentation on 'Recent scientific advances – including CRISPR'.

For a time there had been very few new treatments for acute myeloid leukemia (AML) and Myelodysplasia, and recently there has been an 'avalanche' of new treatments for these diseases. Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, tells us about the extremely positive responses seen in the use of a new monoclonal antibody in combination with azacitidine. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

45th Annual Meeting of the EBMT, 24–27 March 2019, Frankfurt, DE Karthik Ramasamy Oxford University Hospitals, Oxford, UK Interview Topic (English): Clinical decisions based on patient quality-of-life in multiple myeloma For more information and expert opinions in Multiple Myeloma (MM), please visit: www.multiplemyelomahub.com

Chronic myeloid leukemia (CML) stem cells are thought to evade treatment through disruption in the environment within the bone marrow, creating a proinflammatory microenvironment in which there is excessive tumor necrosis factor signaling. In this talk, Adam Mead, PhD, MRCP, FRCPath, from Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines research using single cell genomics and real-world data to predict patients’ risk of relapse after treatment has ceased. This could prevent treatment being administered beyond requirement, although Dr Mead points out two factors that could prevent the widespread utilization of single cell genomics. Dr Mead touches upon the DESTINY study (NCT01804985), which is investigating the de-escalation of imatinib, nilotinib and dasatinib in CML, and the promising rates of treatment-free remission. This video was recorded at the British Society of Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.

During the 1st NCRI AML academy meeting, the AML Global Portal was pleased to speak to Professor Paresh Vyas from the University of Oxford, Oxford, UK about how translational studies may help to improve outcomes for patients with AML.

Prof Paresh Vyas, Professor of Haematology at the University of Oxford, talks about the personalised medicine approach in treating blood cancers. He was speaking at the first of a series of workshops and seminars on personalised medicine at St Anne's College, Oxford, on 21 March 2019, jointly organised by the Centre for Personalised Medicine and the NIHR Oxford Biomedical Research Centre's Partnerships for Health, Wealth and Innovation Theme. The event aimed to identify major social challenges around personalised medicine – developing new knowledge, tools and solutions. Prof Vyas is the Theme Lead for both Haematology and Molecular Diagnostics at the Oxford Biomedical Research Centre.

Thank you video to be shown at My Peak Challenge dinner, 24 September 2017 as a thank you for their fundraising having gone to supporting the CAMELLIA trial in Oxford.

Lecture by Haematologist Paresh Vyas on the treatment of acute leukaemia. Aimed at patients, the lecture explores what leukaemia is, different types of leukaemia and the range of treatments and their outcomes. The key role of research at Oxford in improving treatment is highlighted.

Podcast with Dr Hal Drakesmith. Dr Drakesmith discusses how iron helps us to fight infection, but also how iron can feed the microbes that cause infection. New research may enable us to reduce iron availability to microbes, helping the immune system to fight infection more effectively. © Nuffield Department of Medicine

Senior Research Fellow and Consultant Haematologist Dr Adam Mead outlines the pioneering research within Oxford BRC's Blood theme and how it's helping improve diagnosis and treatment of diseases including leukaemia, lymphoma and red blood cell disorders and also developing state of the art blood transfusion and genetic testing.